Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1541-1549

  Romano, Eloisa ^a   Chora, Inês ^a,b   Manetti, Mirko ^a   Mazzotta, Celestina ^a   Rosa, Irene ^a   Bellando Randone, Silvia ^a   Blagojevic, Jelena ^a   Soares, Raquel ^c   Avouac, Jerôme ^d   Allanore, Yannick ^d   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^a   Guiducci, Serena ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c University of Porto   (Portugal)

^d INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FRIEND LEUKAEMIA INTEGRATION 1 PROTEIN; NEUROPILIN 1; SEMAPHORIN 3A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; FLI1 PROTEIN, HUMAN; SEMA3A PROTEIN, HUMAN; TRANSCRIPTION FACTOR FLI 1;

ADULT; AGED; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; EX VIVO STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; NEOVASCULARIZATION (PATHOLOGY); NRP1 GENE; PATHOGENESIS; PERIPHERAL MICROVASCULOPATHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SKIN BIOPSY; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; WESTERN BLOTTING; ANGIOSCOPY; BIOPSY; BLOOD; CELL CULTURE; COMPLICATION; DEFICIENCY; ENDOTHELIUM CELL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PERIPHERAL VASCULAR DISEASES; PHYSIOLOGY; PROCEDURES; SKIN; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; PERIPHERAL VASCULAR DISEASES; PROTO-ONCOGENE PROTEIN C-FLI-1; SCLERODERMA, SYSTEMIC; SEMAPHORIN-3A; SKIN;

EID: 84941687226     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207483     Document Type: Article

References (48)

1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
2. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis. J Cell Mol Med 2010;14:1241-54.
3. Manetti M, Guiducci S, Romano E, et al. Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. Arthritis Res Ther 2013;15:R165.
4. Larrivée B, Freitas C, Suchting S, et al. Guidance of vascular development: lessons from the nervous system. Circ Res 2009;104:428-41.
5. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997;90:739-51.
6. Kolodkin AL, Levengood DV, Rowe EG, et al. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62.
7. Vander Kool CW, Jusino MA, Perman B, et al. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 2007;104:6152-7.
8. Favier B, AlamA, Barron P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006;108:1243-50.
9. Wang L, Zeng H, Wang P, et al. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 2003;278:48848-60.
10. Becker PM, Waltenberger J, Yachechko R, et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 2005;96:1257-65.
11. Kawamura H, Li X, Goishi K, et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 2008;112:3638-49.
12. Koch S. Neuropilin signaling in angiogenesis. Biochem Soc Trans 2012;40:20-5.
13. Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999;146:233-42.
14. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, et al. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007;282:26294-305.
15. Serini G, Valdembri D, Zanivan S, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003;424:391-7.
16. Maione F, Molla F, Meda C, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 2009;119:3356-72.
17. Gu C, Rodriguez ER, Reimert DV, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003;5:45-57.
18. Arese M, Serini G, Bussolino F. Nervous vascular parallels: Axon guidance and beyond. Int J Dev Biol 2011;55:439-45.
19. Appleton BA, Wu P, Maloney J, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphoring and VEGF binding. EMBO J 2007;26:4902-12.
20. Sakurai A, Doçi CL, Gutkind JS. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Res 2012;22:23-32.
21. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
22. Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012;71:1064-72.
23. Manetti M, Guiducci S, Romano E, et al. Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. Arthritis Rheum 2013;65:247-57.
24. Avouac J, Wipff J, Goldman O, et al. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 2008;58:3550-61.
25. Avouac J, Cagnard N, Distler JH, et al. Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. Arthritis Rheum 2011;63:3552-62.
26. Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011;109:e14-26.
27. Guiducci S, Manetti M, Romano E, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis 2011;70:2011-21.
28. Saigusa R, Asano Y, Taniguchi T, et al. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. Exp Dermatol 2015;24:127-32.
29. Manetti M. Fli1 deficiency and beyond: A unique pathway linking peripheral vasculopathy and dermal fibrosis in systemic sclerosis. Exp Dermatol 2015;24:256-7.
30. Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010;59:153-62.
31. Romano E, Bellando-Randone S, Manetti M, et al. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: An in vitro study. Clin Exp Rheumatol 2015;33(Suppl 91):S148-S152.
32. Borghini A, Manetti M, Nacci F, et al. Systemic sclerosis sera impair angiogenic performance of dermal microvascular endothelial cells: Therapeutic implications of cyclophosphamide. PLoS ONE 2015;10:e0130166.
33. Kitsukawa T, Shimizu M, Sanbo M, et al. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997;19:995-1005.
34. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999;126:4895-902.
35. Mukouyama YS, Gerber HP, Ferrara N, et al. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 2005;32:941-52.
36. Oh H, Takagi H, Otani A, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 2002;99:383-8.
37. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
38. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Impaired angiogenesis in systemic sclerosis: The emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 2011;21:204-10.
39. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
40. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012;14:56-63.
41. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007;56:3448-58.
42. Manetti M, Guiducci S, Romano E, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis 2013;72:1425-7.
43. Cébe Suarez S, Pieren M, Cariolato L, et al. A VEGF-A splice variant defective for heparin sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006;63:2067-77.
44. Kawamura H, Li X, Harper SJ, et al. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008;68:4683-92.
45. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, et al. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 2011;118:816-26.
46. Chora I, Guiducci S, Manetti M, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 2015;14:314-22.
47. Wu YY, Chen YL, Jao YC, et al. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis 2014;17:247-60.
48. Broen JC, Radstake TR, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 2014;10:671-81.